Kornimate/medical-research-clean huggingface dataset:
pulmonary hypertension in trisomy 21 patients

Conditions: Congenital Disorders

Summary: evidence has shown poor outcome for adult patients with pre-operative pulmonary hypertension following closure of an atrial septal defect. life-threatening pulmonary hypertensive crises may occur in these patients when they no longer have an atrial communication to decompress high right heart pressures. this concern has led some to advocate fenestrated patch closure of asds in patients with pulmonary hypertension with the prospect of a repeated procedure in order to close the fenestrations at a later date.

pre-operative resolution of pulmonary hypertension would clearly provide the best long-term outcome for these patients, allowing a definitive surgical procedure. there are no reported cases of resolution of pulmonary hypertension with the use of pulmonary vasodilators allowing successful asd closure. we report the case of a patient with trisomy 21 and a primum atrial septum defect with associated cleft mitral valve who was diagnosed with pulmonary hypertension at 8 days of life. elevated pulmonary pressures were documented by cardiac catheterization during which the patient was found to have minimally responsive pulmonary vasculature to the administration of oxygen. he was started on pulmonary vasodilators which were continued for the following 5 months which resulted in gradual reduction in estimated pa pressure allowing successful closure of the primum asd and repair of the cleft mitral valve. following surgery, he was not restarted on pulmonary vasodilators and has continued to do well. the ability to reverse his pulmonary hypertension through the use of pulmonary vasodilators made him a candidate for his successful, definitive surgical repair. he currently has no residual cardiac problems and requires no cardiac medications. there will be no patient follow-up.

Eligibility criteria:
inclusion criteria: * case report of a patient with trisomy 21 and primum atrial septum defect with associated cleft mitral valve who was diagnosed with pulmonary hypertension at 8 days of life exclusion criteria: * those who do not fit into inclusion criteria

Keywords: pulmonary hypertension sildenafil bosentan trisomy 21 atrial septal defect
bayston multicenter antimicrobial pd catheter safety study

Conditions: End Stage Renal Disease (ESRD)

Summary: the study was designed to establish the safety of the bayston antimicrobial pd catheter that is impregnated with a "cocktail" of three well known anti-microbials

the objective of this clinical investigation is to establish the safety of the bayston antimicrobial peritoneal dialysis catheter in esrd patients initiating capd. the bayston catheter is not expected to cause any safety related complications or reactions other than those described for not-impregnated peritoneal dialysis catheters. thus the objective of this clinical investigation is to evaluate whether the bayston catheter causes any unanticipated serious adverse device effects (usade). the primary hypothesis for this study is that the bayston antimicrobial peritoneal dialysis catheter is a safe catheter for peritoneal dialysis. no claims regarding efficacy will be verified during this clinical investigation. this is a prospective, non-randomized, single-arm, multi-center study involving patients suffering from end stage renal disease who are eligible for treatment with peritoneal dialysis. forty-three (43) patients will be enrolled who will be followed up to 6 months after implantation of the bayston antimicrobial peritoneal dialysis catheter.

Eligibility criteria:
inclusion criteria: * end stage renal disease documented by clinical symptoms and/or laboratory findings * patients scheduled for their first pd catheter implantation * eligible for peritoneal dialysis (capd) * willing and able to attend all study follow-up visits * willing and able to understand and sign the informed consent form exclusion criteria: * a history of allergy to rifampin, trimethoprim or triclosan * use contact lenses or have lens implants * pregnant, lactating or planning to become pregnant during the course of the clinical investigation * recent abdominal surgery, abdominal adhesions, infected abdominal wall, diaphragmatic tears or ileus * respiratory insufficiency * infection: * active infections from successful completion of antibiotic treatment for routine bacterial infection less than 4 weeks of entry into the clinical investigation (screening) * febrile viral infection within 4 weeks of entry into the clinical investigation (screening) * less than 12 weeks from conclusion of therapy for systemic fungal infections to screening * abnormal hematology parameters defined as severe anemia with hemoglobin \<8.5g/dl, white blood cell count of \<3,500/μl and a granulocyte count \<2,000/μl * have collagen-vascular, connective tissue, or bleeding disorders * used an investigational medicinal product, biologic or device within the last 30 days prior to enrollment
apnea of prematurity results in respiratory distress and cyanosis. caffeine citrate can treat it.

Conditions: Apnea of Prematurity

Summary: high-dose caffeine citrate is more effective than low-dose caffeine citrate in the treatment of apnea of prematurity (aop). the high-dose group showed fewer apnea episodes, higher extubation success rate, lower extubation failure rate and shorter duration of oxygen therapy

apnea of prematurity (aop) is a common condition in preterm infants due to immature respiratory control, affecting up to 80% of those under 1000 grams. it can lead to serious complications, including respiratory distress, pulmonary hemorrhage, and developmental delays. caffeine citrate, a methylxanthine, is widely used for aop treatment due to its longer half-life and better absorption compared to theophylline. however, the optimal dosage remains uncertain, with varying practices globally.

Eligibility criteria:
inclusion criteria: * • patients with a gestational age of ≥32 and \<37 weeks at birth on lmp. * diagnosis of apnea of prematurity (aop) established as per operational definition within the first 10 days of life. * either male or female patients exclusion criteria: * • patients diagnosed with hydrops fetalis (evaluated through medical record). * patients presenting with major congenital or chromosomal anomalies such as anencephaly, spina bifida, congenital heart defects (e.g., tetralogy of fallot, transposition of the great arteries), or chromosomal disorders (e.g., trisomy 18, turner syndrome). * presence of a confirmed sepsis through blood culture. * presence of a significant underlying neurological disorder evaluated by history and medical records that could contribute to apnea (e.g., intraventricular hemorrhage with posthemorrhagic hydrocephalus, hypoxic-ischemic encephalopathy) * patients who have been previously treated with caffeine or other methylxanthines for apnea.

Keywords: caffeine citrate apnea prematurity
to assess the efficacy and safety of adalimumab in subjects with moderate to severe hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa

Summary: the trial is a 12-week phase 2 study. subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12 in subjects with moderate to severe hidradenitis suppurativa.


Eligibility criteria:
inclusion criteria: subjects with moderate to severe hs as defined by a hssi \> 8 and at least one of the following: 1. hs \>1 year duration with multiple er or doctors visits related to hs 2. intralesional kenalog injection \>5/year, however none within 2 weeks of entry 3. failed systemic retinoids, but not within 3 months of entry 4. failed at least one prior course of antibiotic therapy, which must not have been administered within 2 weeks of entry to the study (excluding the recommended antibiotic regimen given for evidence of active infection immediately before enrollment) 5. history of surgery (reconstructive), but not within 3 months of entry exclusion criteria: 1. women who are pregnant, nursing, or planning pregnancy within 6 months after the last injection (this includes father's who plan on fathering a child within 6 months after their last injection). 2. use of other systemic anti-inflammatory medication except nsaids and low dose systemic steroids (equal or less than 10 mg daily prednisolone or equivalent). 3. if found to have an active infection, patients must have completed topical or oral antibiotic therapy at least 7 days before first injection. 4. have a known history of serious infections (e.g., hepatitis, pneumonia or pyelonephritis) in the previous 3 months. 5. have or have had an opportunistic infection (e.g., herpes zoster \[shingles\], cytomegalovirus, pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than tb) within 6 months prior to screening. 6. have a history of lymphoproliferative disease, including lymphoma or signs suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location (e.g., nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic area), or splenomegaly. 7. have a concomitant diagnosis or history of congestive heart failure. 8. have a history of latent or active granulomatous infection, including tb, histoplasmosis, or coccidioidomycosis, prior to screening.

Keywords: apocrine glands abcesses
coronary ct angiography evaluation for clinical outcomes: an international multicenter registry

Conditions: Coronary Artery Disease

Summary: the overall objective of confirm2 is to perform the largest cardiovascular phenotype outcomes study ever.

confirm2 is a retrospective and prospective, open-label, international, multicenter observational registry designed to evaluate associations between ccta imaging findings and clinical presentation (cross-sectional) and their ability to predict mortality and major adverse cardiac events (longitudinal) in patients with chronic cad.

Eligibility criteria:
inclusion criteria: * age \>18 years * undergoing clinically indicated ccta with \>64-detector row ct * signed informed consent, including of release of medical information, long term follow-up and health insurance portability and accountability act (hipaa) documentation exclusion criteria: * individuals unable to provide informed consent * non-cardiac illness with life expectancy \< 2 years * pregnancy
study to evaluate the efficacy of rotigotine on parkinson's disease-associated pain

Conditions: Advanced Idiopathic Parkinson's Disease

Summary: this trial is being conducted to compare the impact of rotigotine and placebo on chronic pain associated with parkinson's disease among patients with advanced stages of the disease.


Eligibility criteria:
inclusion criteria: * patient has advanced idiopathic parkinson's disease associated chronic pain assessed by a likert pain scale * patient is taking levodopa with a stable daily dose of at least 200 mg for at least 21 days prior to start * hoehn and yahr stage score of ii to iv * mini-mental state examination (mmse) score ≥ 25 * if an antidepressant drug is taken, the dose must be stable for at least 21 days exclusion criteria: * therapy with a dopamine agonist within 21 days prior to start * discontinuation from previous dopamine agonist therapy due to lack of efficacy * therapy with dopamine-modulating substances 21 days prior to start * therapy with analgesics for the treatment for pain, unless the dose has been stable * chronic alcohol or drug abuse * medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the patient's ability to participate in this study * hypersensitivity to any components of the investigational medicinal product (imp) or comparative drugs * atypical parkinson's disease syndrome due to drugs * history of deep brain stimulation * significant skin disease that would make transdermal drug use inappropriate * electroconvulsive therapy within 12 weeks prior to start * evidence of an impulse control disorder * previous diagnosis of severe restless legs syndrome * chronic migraine * severe depression * symptomatic orthostatic hypotension

Keywords: parkinson's disease rotigotine chronic pain nonmotor symptoms
the effects and predictors of patella taping in the treatment of patellafemoral pain syndrome

Conditions: Patellofemoral Pain Syndrome

Summary: background: taping has been used for more than 20 years for patellofemoral pain syndrome (pfps) but the effectiveness is still controversial. purpose: this prospective study was conducted to investigate the effect and predictors of effectiveness of taping in treating pfps. study design: prospective cohort study methods: one hundred consecutive patients with the diagnosis of pfps were included in the study. factors including sex, age, body mass index (bmi), q angle, lateral patella displacement (lpd), lateral patellofemoral angle (lpa) and pre-taping pain score were measured. one well-trained therapist applied adhesive tape to each patient by mcconnell approach. before and after taping, patients completed a visual analog pain scale (vas) after performing a step-down from an 8-inch platform. paired-t test was used for the difference of the vas score measured before and after taping. patients with improvement of more than 1 point in vas score after taping were considered responsible, and others were non-responsible. the results were analyzed by logistic regression.


Eligibility criteria:
inclusion criteria: * (1) between the age of 20 to 60 years, (2) antero-, retro-, or peri-patellar pain from at least two of the following: prolonged sitting, ascending or descending stairs, prolonged walking, squatting, and (3) insidious onset of symptoms unrelated to a traumatic incident. exclusion criteria: * (1) symptoms or signs of any intrarticular derangement of the knee joint, such as effusion, ligament laxity, and meniscal tear, (2) tenderness over the patella tendon, iliotibial band, or pes anserinus tendons, (3) osgood-schlatter disease or sinding-larsen-joahanssen syndromes, (4) referral pain from hip or lumbar region, (5) a history of patellar dislocation, previous knee surgery or infection, (6) malignancy, (7) present pregnancy, (8) recent treatment for the pfps, such as physiotherapy, non-steroid anti-inflammatory or corticosteroid medication, (9) advanced osteoarthritis of the knee joint.
a research registry on aggressive pitnets

Conditions: Endocrine Tumor

Summary: to allow the identification of markers, it is necessary to extend research networks more widely to collect and properly explore aggressive pituitary tumours. the multidisciplinary consultation meeting (rcp), organised by the reference centre for rare diseases of the pituitary gland, dedicated to aggressive pituitary tumours and carcinomas (hypocare), which is unique in france and brings together national experts, currently makes it possible to orientate the management of patients with an aggressive pituitary tumour. with more than 80 patient files discussed since its inception, the patient cohort via the hypocare rcp is one of the largest both nationally and internationally. at present, this data source is only dedicated to the clinical management of the files without the possibility of carrying out research work


Eligibility criteria:
* inclusion criteria : * patients with a diagnosis of pituitary tumour * patients whose file has been presented to the national hypocare rcp * exclusion criteria : * patients objecting to participating in this research

Keywords: endocrine tumor reference centre rare diseases transcriptoms
effects of connective tissue massage in patients with fibromyalgia

Conditions: Fibromyalgia

Summary: connective tissue massage (ctm), one of the various manual therapy techniques for fms, produces local mechanical effects on mast cells in the connective tissue with short and long tractions, thereby reducing sympathetic activity and producing vasodilation. the aim of the study was to compare the effectiveness of self myofascial release technique and connective tissue massage in patients with fms. at least 30 fms patients will be included in the study. fibromyalgia impact questionnaire, pain, quality of life and sleep quality will be evaluated. ctm will be practiced to study group and foam roller will be practiced to control group.

fibromyalgia syndrome (fms) is associated with chronic widespread pain and at least eleven positive tender points out of 18 according to the american college of rheumatology (acr) 1990 criteria. it is often associated with symptoms such as decreased physical strength, fatigue, sleep disturbances, gastrointestinal disorders and psychiatric disorders such as depression. connective tissue massage (ctm), one of the various manual therapy techniques for fms, produces local mechanical effects on mast cells in the connective tissue with short and long tractions, thereby reducing sympathetic activity and producing vasodilation. in the last two decades, massage applications using tools of various densities, materials, shapes and sizes (such as foam roller (fr), roller massagers, sticks or balls) and actively self-administered by individuals have rapidly gained popularity. the aim of the study was to compare the effectiveness of self myofascial release technique and connective tissue massage in patients with fms. at least 30 fms patients will be included in the study. fibromyalgia impact questionnaire, pain, quality of life and sleep quality will be evaluated. ctm will be practiced to study group and foam roller will be practiced to control group. treatments will be applied for 6 weeks, 2 days a week for a total of 12 sessions.

Eligibility criteria:
inclusion criteria: * being a woman * being diagnosed with fms, * being between the ages of 18-65 and volunteering. exclusion criteria: * neurological, infectious, endocrine and other inflammatory rheumatic diseases, severe psychological disorders, any condition that prevents exercise (advanced cardiac respiratory or orthopedic problems), * malignancy * being pregnant

Keywords: fibromyalgia connective tissue massage myofascial release foam roller
host modulatory effects of β-glucan on localized aggressive periodontitis

Conditions: Localized Aggressive Periodontitis

Summary: combining the non-surgical therapy with a well-tolerated substance that can stimulate protective immune responses like b-glucan, might effectively mount resolution pathways contributing to resolving of the chronic lesion observed in aggressive forms of periodontal disease.

aim: to investigate the efficacy of β-glucan supplementation to non-surgical periodontal therapy in localized aggressive periodontitis (lap) patients. method: 30 subjects were randomly and equally assigned to receive scaling and root planing; either with placebo pills (group i) or β-glucan (100 mg/once a day) (group ii), for 40 days. subjects were clinically monitored on day 0 and day 91. gingival samples were harvested from hopeless teeth sites to be investigated histologically and immunohistochemically using matrix metalloproteinase (mmp)-1 and 9 antibodies form each patient; at the same time intervals.

Eligibility criteria:
inclusion criteria: * except for periodontitis, patients were systemically healthy as evaluated by modified cornell medical index. * no more than two teeth other than first molars and incisors, with probing depth (pd) ≥ 5mm, bleeding on probing (bop), and clinical attachment level (cal) ≥ 5mm. * rapid rate of attachment loss and bone destruction. * a radiographic examination revealing an evidence of moderate to severe vertical bone loss around permanent incisors and first molar teeth. * every patient should have at least 20 teeth excluding third (3rd) molars, and at least an extraction-indicated tooth for a dento-periodontal affection. * familial aggregation. exclusion criteria: * previous subgingival scaling and root planing, allergy to β-glucan, smoking, former smoking, pregnancy, need of antibiotic coverage for routine dental therapy, antibiotic therapy in the previous 6 months and allergy to chlorhexidine.
testosterone and pain sensitivity

Conditions: Low Testosterone; Hypogonadism; Pain

Summary: this research is being done to see whether testosterone replacement in men who take opioid-based pain medications and have low testosterone levels will show improvement in pain tolerance, pain perception and quality of life. some men who take opioid-based medications (narcotics) for pain develop low testosterone levels. research has shown that low testosterone levels may make a person more sensitive to pain. this means that if a person with a painful condition develops low testosterone level as a result of his pain medications, he might become more sensitive to pain and so may need higher doses of pain medications for pain control. testosterone is a male hormone that is important for sperm production and the development of male characteristics such as muscle mass and strength, fat distribution, bone mass and sex drive. testosterone hormone replacement therapy has been used for decades to treat men with low testosterone levels (male hypogonadism). testosterone replacement therapies are available in the form of an injection into the muscle, implants under the skin, oral capsules taken by mouth, topical gels applied to the skin, and skin patches. this study will use fortesta®, a topical testosterone gel (t-gel) absorbed into the skin. fortesta® is currently on the market as an fda-approved treatment of male hypogonadism (low testosterone levels). men with non-cancer related pain who take opioid-based medications for pain and have low testosterone levels may join this study. (a low testosterone level is defined as early morning (before noon) blood testosterone level of 300 ng/dl or less, or a free testosterone of 50 ng/dl or less)).


Eligibility criteria:
inclusion criteria: * men * 18 years of age and older * serum total testosterone level \<300 ng/dl or free testosterone \< 50 pg/ml * consumption of at least 10 mg of hydrocodone (or analgesic equivalent of another opioid) for at least 4 weeks * absence of hospitalization in past 2 months * no acute illness in past 2 months * no prior history of any form of hypogonadism * no current anabolic therapy (growth hormone, dhea, etc) * no current use or consumption in past 2 months of glucocorticoids and melatonin * normal digital rectal examination * normal psa level exclusion criteria: * liver enzymes \>3 times upper limit of normal * serum creatinine \> 2 times upper limit of normal * neurological disease * active psychiatric illness * any addictive and/or illicit drug use * alcoholism (\>10 drinks/week) * patients currently receiving glucocorticoids, melatonin or anabolic agents * hospitalization in past 2 months * acute illness in past 2 months * consumption of \< 20 mg of hydrocodone (or analgesic equivalent of another opioid) * severe bph * psa \>4.0 ng/ml * prostate cancer * breast cancer * any cancer or cancer related pain * history of alcohol abuse * known peripheral neuropathy (any etiology) or peripheral vascular disease (including raynaud's disease), which may interfere with pain testing * concurrent warfarin treatment

Keywords: hypogonadism low testosterone pain